RPRX
Royalty Pharma Plc
NASDAQ · Healthcare · Biotechnology · US
$58.75
−3.04%Price chart
Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10
ValuationView details →
P/E (Fwd)
12.6x
EV/EBITDA
21.7x
Market Cap
$26.16B
MomentumView details →
1D Return
−3.04%
YTD Return
+53.91%
RSI (14)
44.9
ValuationView details →
P/E (Fwd)
12.6x
EV/EBITDA
21.7x
Market Cap
$26.16B
RSI (14)
44.9
MomentumView details →
1D Return
−3.04%
YTD Return
+53.91%
SummaryUpdated Jun 1, 2026
Royalty Pharma plc (NASDAQ:RPRX) is a leading buyer of biopharmaceutical royalties and funder of innovation in the healthcare industry. Founded in 1996 and based in New York, the company went public in June 2020. Royalty Pharma operates as a specialized investment firm that acquires royalty streams from successful pharmaceutical and biotechnology products, providing capital to innovators while generating returns for shareholders through predictable cash flows from marketed therapies and development-stage products.
Similar companies
Latest newsMore news →
Royalty Pharma agreed to provide $100 million in funding to Zealand Pharma in exchange for economics related to rusfertide (PTG-300), a potential first-in-class therapy for polycythemia vera.29d agoRoyalty Pharma plc reported its financial results for the second quarter of 2026, with Portfolio Receipts growth of 6% to $773 million and Royalty Receipts growth of 14%, and raised its full year 2026 guidance for Portfolio Receipts to $3,400 million to $3,500 million.37d ago